The University of Chicago Header Logo

TIGIT is a key inhibitory checkpoint receptor in lymphoma.

TIGIT is a key inhibitory checkpoint receptor in lymphoma. J Immunother Cancer. 2023 06; 11(6).

View in: PubMed